Outlook Therapeutics Sets $485 Per Vial Wholesale Price for LYTENAVA
OTLK has more than doubled off its 52-week low of $0.161 on light trading volume (0.4× avg).
Summary
Outlook Therapeutics disclosed the wholesale acquisition cost for LYTENAVA at $485 per vial, marking the first pricing detail for its FDA-approved wet AMD treatment.
Key Events · Product Development and Regulatory · OTLK
-
LYTENAVA Wholesale Price Set
Effective September 16, 2026, the wholesale acquisition cost for LYTENAVA in the United States has been established at $485 per vial.
-
First Commercial Pricing Disclosure
This is the first public disclosure of LYTENAVA pricing since FDA approval in July 2026, providing a basis for revenue modeling and reimbursement discussions.
-
Launch Funding in Place
The pricing announcement follows the $55 million public offering completed in August 2026, which was specifically intended to fund the LYTENAVA commercial launch.
-
Commercial Milestone
Setting the wholesale acquisition cost is a key step toward commercial availability, enabling distribution and payer negotiations for the first FDA-approved ophthalmic bevacizumab.
Analysis · OTLK · Life Sciences
The wholesale acquisition cost for LYTENAVA has been set at $485 per vial, marking the first concrete pricing disclosure for the newly approved wet AMD treatment. This is a critical commercial milestone following FDA approval in July 2026 and the recent $55 million public offering to fund the launch. The price point will directly influence revenue projections, reimbursement negotiations, and market adoption for the company's first commercial product.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 29.7% of the 1516 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.48%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OTLK was trading at $0.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $158.9M. The 52-week trading range was $0.16 to $2.54. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.